BIIB logo

Biogen

BIIB · What the business does, what can go wrong, and how options sellers approach it

What it does

Biogen is a biopharmaceutical company focused on neurological and neurodegenerative diseases, along with some rare diseases. Its medicines treat conditions such as multiple sclerosis, spinal muscular atrophy, Alzheimer's disease, Friedreich's ataxia, postpartum depression and a genetic form of ALS.

How it makes money

Biogen sells prescription drugs and also earns money from partnerships. Its multiple sclerosis products have long been a major revenue source, though that franchise has been shrinking as generics and competing drugs arrive. It also receives royalties and collaboration revenue tied to the CD20 agreement with Roche, and shares economics with partners on several newer products. Newer products are meant to replace the older ones as they fade.

Why investors own it

Investors typically look at Biogen as an established drugmaker with a deep neurology focus, a history of producing cash, and a pipeline that could renew growth. Some see it as a way to own a company tied to Alzheimer's and other brain diseases, where medical need is large. Others follow it for exposure to rare disease treatments alongside its neurology business.

What can go wrong

  • The multiple sclerosis business may decline faster than new drugs can offset.
  • Clinical trials can fail, and regulators can delay or reject approvals.
  • Alzheimer's treatments face questions around safety, cost, insurance coverage and how quickly patients adopt them.
  • Partnerships can change, and Biogen depends on partners for some key products.
  • Drug pricing pressure from governments and insurers can cut into sales.
  • Acquisitions can disappoint or add costs.

What to watch

  • Multiple sclerosis revenue trends
  • Leqembi uptake and any safety updates
  • Pipeline trial readouts and regulatory decisions
  • Performance of Skyclarys, Zurzuvae and Qalsody
  • Roche collaboration revenue
  • Patent expirations and generic competition
  • Business development and partnership news

Options income angle

Options on BIIB are generally liquid, with listed contracts across many strikes and expirations, though trading is usually thinner than in the largest pharma names. Implied volatility tends to rise ahead of clinical trial results, FDA decisions, earnings reports and major Alzheimer's news. One caution: a single trial or regulatory headline can move the stock sharply and quickly, which can cause losses on a short call or short put that go beyond the premium collected. Selling premium into a known catalyst deserves particular care.

What the latest 10-K says

A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 6, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The filing in brief

Biogen's total revenue rose 2.2% to $9,890.6 million in 2025, but the mix is shifting. Multiple sclerosis (MS) sales keep falling to generic and biosimilar (near-copy biologic) competition, while rare disease products and new launches grow. Diluted earnings per share fell 21.4%, pressured by higher upfront deal payments and litigation charges.

How the business did

  • Product revenue, net decreased 1.3% to $7,119.4 million. MS revenue fell 7.1% to $4,038.9 million. TECFIDERA dropped 29.7% to $679.7 million on generics, and TYSABRI fell 2.9% to $1,665.4 million on a biosimilar. VUMERITY rose 18.9% to $746.8 million.
  • Rare disease revenue rose 8.4% to $2,154.2 million, led by SKYCLARYS at $520.5 million. ZURZUVAE reached $195.1 million, and Alzheimer's collaboration revenue (the company's 50.0% share of LEQEMBI) was $177.7 million.
  • Total cost and expense rose 7.3% to $8,334.1 million. Acquired in-process R&D, upfront and milestone expense was $471.8 million versus $61.5 million. The company also booked a $104.9 million litigation charge in cost of sales and $139.5 million of litigation expense in other expense, including an agreement in principle to resolve claims tied to the Convergence acquisition. Income before tax was $1,556.5 million versus $1,906.0 million.
  • Net cash flow from operations was $2,204.6 million versus $2,875.5 million, partly because of higher tax payments of approximately $864.0 million, which the filing attributes to timing. Cash, cash equivalents and marketable securities were approximately $4.2 billion. No shares were repurchased, and approximately $2.1 billion remained under the buyback authorization.

Risks specific to this company

  • MS erosion: TECFIDERA faces multiple generic entrants, and a European patent was revoked in November 2025. TYSABRI faces a biosimilar. The company expects both to keep declining.
  • Dependence on Genentech: Revenue from anti-CD20 programs was $1,860.6 million, including $1,414.9 million of royalties on OCREVUS. The company does not control those sales. RITUXAN biosimilars have significantly hurt the profit-sharing arrangement.
  • LEQEMBI and Eisai: LEQEMBI is in the early stages of launch and depends on Eisai's reimbursement and commercial efforts. In June 2025 the company filed for arbitration over the budget and commercialization plan for the European territory.
  • Drug pricing policy: The IRA (a U.S. law that lets Medicare negotiate some drug prices) and Medicare Part D changes had an unfavorable impact of approximately $90.0 million on 2025 revenue. A May 2025 executive order proposes tying U.S. prices to those in other developed countries, and the company says it could cut prices for some products.
  • Supply concentration: Certain SKYCLARYS starting materials rely on a single supplier in China. One contract research organization handles a substantial portion of clinical trial work. A contract manufacturer for IMRALDI and BENEPALI was acquired in 2024. Pharmaceutical import investigations under Section 232 add tariff uncertainty, though the company does not expect tariffs to materially hurt 2026 operations.
  • Debt and milestone obligations: Long-term debt was $6.3 billion. The company could owe potential milestone payments to partners of up to approximately $5.3 billion, which are not recorded because they were not considered probable. The filing says these obligations could limit flexibility.

What management is watching

  • MS in 2026: Management expects total MS revenue to keep declining, with accelerating TECFIDERA generic competition in parts of the E.U., partly offset by VUMERITY demand.
  • Rare disease and launches: Growth is expected from SKYCLARYS and QALSODY and from U.S. ZURZUVAE. Global SPINRAZA revenue is expected to be relatively flat.
  • Regulatory dates: The FDA action date (the target date for its decision) for a SPINRAZA high dose is April 3, 2026. For the LEQEMBI IQLIK subcutaneous autoinjector as a weekly starting dose, it is May 24, 2026. A Phase 3 salanersen study is expected to begin in 2026, triggering a $45.0 million milestone.
  • Spending: Core R&D is expected to increase slightly, mostly in late-stage programs, while selling, general and administrative expense is expected to be relatively flat. The Fit for Growth cost program generated approximately $1.0 billion in gross operating expense savings by the end of 2025.
  • Net interest: Management anticipates lower net interest expense in 2026 on higher interest income.

What the latest 10-Q says

A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed October 28, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The quarter in brief

Biogen's third-quarter revenue grew, helped by the Apellis acquisition, but the quarter ended with a pre-tax loss. Total revenue was $2,804.1 million, up 10.6%, while total cost and expense rose 42.3%. Diluted earnings per share decreased $3.31 or 104.4%.

How the business did

  • Revenue: Total revenue was $2,804.1 million versus $2,534.7 million a year earlier. For nine months it was $8,017.9 million versus $7,611.2 million, up 5.3%. Apellis products SYFOVRE and EMPAVELI added $242.8 million of U.S. specialized immunology revenue. Rare disease revenue rose $143.0 million, or 26.8%, led by the high-dose SPINRAZA launch, SKYCLARYS and QALSODY.
  • Declines: Multiple sclerosis (MS) revenue fell $142.2 million, or 13.4%. TECFIDERA revenue fell 51.2% to $82.0 million as generic competitors entered. Biosimilar revenue fell 15.7%.
  • Costs and profit: Total cost and expense was $2,813.1 million versus $1,977.4 million. Acquired in-process research and development (R&D) expense was $283.8 million, mostly a $225.0 million upfront payment for RayThera. Restructuring charges were $66.5 million. Cost of sales also carried amortization of the "step-up" in acquired inventory, meaning inventory recorded above cost at acquisition and expensed as it is sold. The result was a pre-tax loss of $(9.0) million, versus income of $557.3 million a year earlier.
  • Cash and capital: Operating cash flow for nine months was $1,735.2 million versus $1,692.7 million. Cash and marketable securities fell to $1,303.9 million from $4,247.6 million after the Apellis purchase. Total borrowings were $7,692.0 million. The company repurchased no shares in the period.

What management is watching

  • MS and SPINRAZA: Management expects total MS revenue to keep declining, with TECFIDERA hit by generics and TYSABRI by a biosimilar. It expects SPINRAZA revenue to normalize as patients finish converting to the high-dose regimen and the one-time transition dose benefit fades.
  • Spending and interest: Management expects core R&D expense and selling, general and administrative expense to increase in 2026, citing late-stage programs, Apellis integration and product launches. It also expects higher net interest expense in 2026 than in 2025.
  • Policy and trade: Management does not expect current tariffs to have a material adverse effect on 2026 operations. It also does not believe the new Medicare Part B pricing model, which begins January 1, 2027, will materially affect 2027.

New or changed risks

  • Apellis integration: The risk factors now say the benefits of the acquisition depend on how well Apellis is integrated and on commercializing EMPAVELI and SYFOVRE. EMPAVELI is described as early in the launch of a new indication.
  • Pharmaceutical tariffs: A new Proclamation imposes a 100% tariff on imports of patented pharmaceuticals, biologics and associated ingredients, subject to exemptions and reduced rates. The company warns further trade measures could follow.
  • Drug pricing rule: CMS published a final rule for the Global Benchmark for Efficient Drug Pricing Model. The company warns that additional most-favored-nation pricing targets could materially harm its business.
  • LEQEMBI subcutaneous launch: After the FDA's July 2026 approval, the benefit depends on a successful launch and on patient and physician adoption.

Follow BIIB in Kortex

The Kortex app shows BIIB's price, options chain and IV rank, and answers your questions from live market data and SEC filings.

Free to download.

Learn the strategies

More stock briefs

For education only, not financial advice. Options involve risk and are not suitable for every investor.